Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414911 | 0.88 | MEN1 (0.43) | PDE4BCKS1BSKP1SKP2JAK1 | |
| SCHEMBL16414912 | 0.88 | MEN1 (0.43) | PDE4BCKS1BSKP1SKP2JAK1 | |
| SCHEMBL30879093 | 0.82 | MERTK (0.47) | PDE4BCKS1BSKP1SKP2JAK1 | |
| SCHEMBL16415194 | 0.78 | MERTK (0.41) | PDE4BCKS1BSKP1SKP2JAK1 | |
| SCHEMBL4714436 | 0.73 | KMT2A (0.45) | MEN1KMT2A | |
| SCHEMBL4714437 | 0.73 | KMT2A (0.45) | MEN1KMT2A | |
| SCHEMBL30879016 | 0.72 | ALDH1A1 (0.52) | MERTKBTKMEN1KMT2A | |
| SCHEMBL22001725 | 0.70 | JAK1 (0.69) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL4716352 | 0.70 | HPGD (0.41) | CKS1BSKP1SKP2JAK1JAK2 | |
| SCHEMBL4716347 | 0.70 | HPGD (0.41) | CKS1BSKP1SKP2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PDE4B 2838/4885CKS1B 33/4885SKP1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.